Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Colorcon
Boehringer Ingelheim
McKinsey
Accenture
Argus Health
Fish and Richardson
UBS
Fuji
US Department of Justice

Generated: May 22, 2018

DrugPatentWatch Database Preview

Details for Patent: 7,828,787

« Back to Dashboard

Which drugs does patent 7,828,787 protect, and when does it expire?

Patent 7,828,787 protects NAROPIN and is included in one NDA.

This patent has twenty-four patent family members in twenty countries.
Summary for Patent: 7,828,787
Title:Connector for packaging containing medical fluids and packaging for medical fluids
Abstract: The disclosure relates to a connector for packaging containing medical fluids, in particular infusion or transfusion bags, including a tubular connection part for receiving a spike for the withdrawal of fluid, and having a lower opening on the packaging side and an upper opening on the connection side. A self-sealing membrane, which is pierced by the spike, is located in the connection part. The membrane has an upper, annular section leading into a lower, plate-shaped section, said annular section of the membrane surrounding the spike in a sealing manner, when the latter pierces the plate-shaped section. The membrane acts as a guide for the spike and also reseals the connector, once the spike has been removed.
Inventor(s): Brandenburger; Torsten (Niddatal, DE), Rahimy; Ismael (Friedberg, DE)
Assignee: Fresenius Kabi Deutschland GmbH (Bad Homburg, DE)
Application Number:10/514,817
Patent Claim Types:
see list of patent claims
Device;

Drugs Protected by US Patent 7,828,787

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Fresenius Kabi Usa NAROPIN ropivacaine hydrochloride SOLUTION;INJECTION 020533-006 Sep 24, 1996 AP RX Yes No ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Fresenius Kabi Usa NAROPIN ropivacaine hydrochloride SOLUTION;INJECTION 020533-007 Sep 24, 1996 AP RX Yes No ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Foreign Priority and PCT Information for Patent: 7,828,787

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
Germany102 23 560May 27, 2002
PCT Information
PCT FiledFebruary 24, 2003PCT Application Number:PCT/EP03/01847
PCT Publication Date:December 04, 2003PCT Publication Number: WO03/099191

Non-Orange Book US Patents Family Members for Patent 7,828,787

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,118,802 Connector for packaging containing medical fluids and packaging for medical fluids ➤ Sign Up
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

McKesson
Dow
Medtronic
Citi
QuintilesIMS
US Department of Justice
Chinese Patent Office
AstraZeneca
Colorcon

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.